Education
About Us
Working with TipRanks
Follow Us
CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
RESEARCH TOOLSreports
GDTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $4.05
Previous CloseN/A
Volume107.31K
Average Volume (3M)7.13K
Market Cap
$25.35M
Enterprise Value$22.62M
Total Cash (Recent Filing)$3.64M
Total Debt (Recent Filing)$463.25K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding12,550,000
10 Day Avg. Volume7,940
30 Day Avg. Volume7,126
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)3.69
Price to Sales (P/S)0.00
P/FCF Ratio-6.47
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue22.65
Enterprise Value/Gross Profit-182.62
Enterprise Value/Ebitda-1.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CytoMed Therapeutics Limited News
PremiumCompany Announcements
CytoMed Therapeutics Issues Shares to Executives as Compensation
PremiumCompany Announcements
CytoMed Therapeutics Schedules AGM for June 2025
PremiumCompany Announcements
CytoMed Therapeutics Reports 2024 Financial Results and Clinical Progress
PremiumCompany Announcements
CytoMed Therapeutics Announces 2024 Financial Results and Clinical Advances
PremiumCompany Announcements
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in IndiaOptions Prices
Currently, No data available
---
Ownership Overview
26.57% Insiders
0.04%
Mutual Funds
0.04% Other Institutional Investors
73.35% Public Companies and
Individual Investors
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $1.20 and its highest was $4.05 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $25.35M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
CytoMed Therapeutics Limited’s upcoming earnings report date is Nov 14, 2025 which is in 118 days.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 12,550,000 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
CytoMed Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $171.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.37%
12-Months-Change
Fundamentals
Return on Equity
-24.97%
Trailing 12-Months
Asset Growth
-21.30%
Trailing 12-Months
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Technical Analysis
Tempest Therapeutics
―
VYNE Therapeutics
―
Clene
―
PolyPid
―
Barinthus Biotherapeutics
―